Among 6 analysts covering Genocea Biosciences (NASDAQ:GNCA), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Genocea Biosciences had 14 analyst reports since August 6, 2015 according to SRatingsIntel. UBS initiated Genocea Biosciences, Inc. (NASDAQ:GNCA) rating on Thursday, December 17. UBS has “Buy” rating and $15 target. The stock of Genocea Biosciences, Inc. (NASDAQ:GNCA) earned “Buy” rating by Needham on Thursday, September 29. As per Tuesday, September 26, the company rating was downgraded by Needham. Cowen & Co maintained the shares of GNCA in report on Monday, July 24 with “Buy” rating. On Friday, November 3 the stock rating was maintained by Needham with “Hold”. The stock of Genocea Biosciences, Inc. (NASDAQ:GNCA) has “Buy” rating given on Monday, September 25 by Cowen & Co. On Monday, July 24 the stock rating was upgraded by Needham to “Buy”. The firm has “Buy” rating by Needham given on Tuesday, October 20. Cowen & Co maintained the stock with “Buy” rating in Wednesday, August 9 report. The firm has “Outperform” rating by FBR Capital given on Monday, October 19. See Genocea Biosciences, Inc. (NASDAQ:GNCA) latest ratings:
03/11/2017 Broker: Needham Rating: Hold Maintain
26/09/2017 Broker: Needham Rating: Hold Downgrade
25/09/2017 Broker: Cowen & Co Rating: Buy New Target: $10.0 Maintain
26/09/2017 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Hold Downgrade
09/08/2017 Broker: Cowen & Co Rating: Buy New Target: $40.0000 Maintain
24/07/2017 Broker: Cowen & Co Rating: Buy New Target: $40.0000 Maintain
24/07/2017 Broker: Needham Old Rating: Hold New Rating: Buy Upgrade
Insider trade amounting to exactly $2,240,139 USD was revealed in a form submitted to the Washington-based SEC on 04-01-2018. According to which, Glenn Baity, the EVP AND GC of Acadia Pharmaceuticals Inc also an insider of the California-based company had unloaded precisely 74,321 shares – ( at $30.1 per share ). Currently, Mr. Glenn, possess 70,113 shares, which accounts for 0.06% of the company’s market cap. The insider’s activity definitely generated quite an interest in the stock community.
The stock decreased 5.36% or $0.06 during the last trading session, reaching $1.06. About 631,510 shares traded. Genocea Biosciences, Inc. (NASDAQ:GNCA) has risen 67.22% since January 9, 2017 and is uptrending. It has outperformed by 50.52% the S&P500.
Genocea Biosciences, Inc., a biopharmaceutical company, engages in developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. The company has market cap of $30.43 million. The firm uses AnTigen Lead Acquisition System , its proprietary discovery platform to build a pipeline of immunotherapies and its first neoantigen cancer vaccine. It currently has negative earnings. The Company’s lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase 2 trial for the treatment of genital herpes infections.
Analysts await ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report earnings on February, 27. They expect $-0.58 EPS, up 10.77% or $0.07 from last year’s $-0.65 per share. After $-0.53 actual EPS reported by ACADIA Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 9.43% negative EPS growth.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company has market cap of $3.37 billion. The Company’s lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson??s disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer??s disease psychosis. It currently has negative earnings. The firm has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain.
The stock decreased 6.19% or $1.79 during the last trading session, reaching $27.11. About 3.36 million shares traded or 115.49% up from the average. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 15.19% since January 9, 2017 and is downtrending. It has underperformed by 31.89% the S&P500.
Investors sentiment decreased to 1.01 in 2017 Q3. Its down 0.04, from 1.05 in 2017Q2. It is negative, as 25 investors sold ACADIA Pharmaceuticals Inc. shares while 58 reduced holdings. 32 funds opened positions while 52 raised stakes. 113.55 million shares or 1.98% less from 115.85 million shares in 2017Q2 were reported. Bb&T Securities Lc has invested 0% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Ubs Asset Management Americas Incorporated invested 0.03% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). 4,380 are held by Manufacturers Life Insur The. Moreover, Ray Gerald L Ltd has 0.94% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Eventide Asset Management Limited Com reported 334,700 shares. Moreover, Kistler has 0% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 149 shares. Alps Advisors accumulated 120,544 shares. Columbus Circle Invsts invested in 0.03% or 53,984 shares. Rhumbline Advisers accumulated 111,094 shares. Fred Alger has invested 0.35% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Next Fin Group Inc has 200 shares. Atlantic Tru Gp Ltd Llc reported 15,195 shares. Voya Invest Management Lc invested in 47,447 shares or 0% of the stock. Deutsche Savings Bank Ag invested 0.03% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Proshare Advisors Ltd Liability Company stated it has 71,245 shares.
Since August 9, 2017, it had 0 buys, and 5 selling transactions for $5.95 million activity. $2.24M worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was sold by Baity Glenn on Tuesday, January 2. 25,000 shares valued at $751,543 were sold by Brege Laura on Tuesday, January 2.
Among 12 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 9 have Buy rating, 0 Sell and 3 Hold. Therefore 75% are positive. ACADIA Pharmaceuticals has $61.0 highest and $34 lowest target. $50.54’s average target is 86.43% above currents $27.11 stock price. ACADIA Pharmaceuticals had 33 analyst reports since August 7, 2015 according to SRatingsIntel. As per Friday, November 11, the company rating was initiated by Goldman Sachs. As per Wednesday, August 9, the company rating was maintained by Cowen & Co. The company was maintained on Friday, September 15 by Needham. The rating was downgraded by Piper Jaffray on Friday, August 7 to “Neutral”. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, October 5. The stock has “Overweight” rating by Piper Jaffray on Friday, January 22. The firm has “Buy” rating given on Monday, September 4 by Jefferies. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Market Perform” rating given on Tuesday, May 3 by Leerink Swann. On Tuesday, October 4 the stock rating was initiated by Leerink Swann with “Mkt Perform”. Piper Jaffray maintained the stock with “Buy” rating in Wednesday, August 9 report.